Lafeber Melvin, Evers Andrea W M, Klok Frederikus A
Erasmus MC, afd. Interne Geneeskunde, Rotterdam.
Contact: Melvin Lafeber (
Ned Tijdschr Geneeskd. 2023 Mar 8;167:D7402.
Statins are effective drugs that can reduce the risk of new cardiovascular events. Although in randomized, placebo-controlled trials statins are associated with a low risk of mild muscle complaints such as myalgia, in daily practice up to 30% of patients report complaints attributed to statin use. Two recent studies have shown statin-associated muscle complaints are mainly related to the nocebo effect. The nocebo effect is a decrease in benefit and/or a new onset or worsening of adverse effects due to an expectation of harm associated with the treatment. Statins face reputational challenges due to a vast amount of negative attention on the internet. We need to address the nocebo effect by managing the perception of statins and provide patients with objective information about statin treatment, reduce the negative expectations, and placing discussion about the likelihood of adverse effects into the context of treatment benefit.
他汀类药物是有效的药物,可降低新发心血管事件的风险。尽管在随机、安慰剂对照试验中,他汀类药物与肌肉轻微不适(如肌痛)的低风险相关,但在日常实践中,高达30%的患者报告有归因于他汀类药物使用的不适症状。最近的两项研究表明,他汀类药物相关的肌肉不适主要与反安慰剂效应有关。反安慰剂效应是指由于对与治疗相关的危害的预期,导致益处减少和/或不良反应的新出现或恶化。由于互联网上大量的负面关注,他汀类药物面临声誉挑战。我们需要通过管理对他汀类药物的认知来应对反安慰剂效应,为患者提供有关他汀类药物治疗的客观信息,减少负面期望,并将关于不良反应可能性的讨论置于治疗益处的背景下。